Related Experiment Video
Updated: Mar 22, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Biomarkers associated with checkpoint inhibitors
G Manson1, J Norwood1, A Marabelle2
1Department of Hematology, CHU Rennes, Rennes.
Abstract:
Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Insights
Checkpoint inhibitors (CPI) show cancer treatment efficacy but cause side effects and varied responses. Biomarkers predicting CPI effectiveness and immune-related adverse events (irAE) are crucial for patient selection.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Checkpoint inhibitors (CPI), including anti-CTLA4 and anti-PD1/PD-L1 antibodies, are effective cancer treatments.
- Patient response to CPI varies, with only subgroups benefiting.
- CPI therapy can lead to severe immune-related adverse events (irAE).
Purpose of the Study:
- To review key biomarkers associated with CPI efficacy.
- To identify biomarkers linked to CPI-induced toxicity (irAE).
- To guide patient selection for CPI therapy.
Main Methods:
- Literature review of studies on CPI biomarkers.
- Analysis of pharmacodynamic and clinical benefit markers.
- Assessment of markers correlating with irAE development.
Main Results:
- Several biomarkers are associated with CPI efficacy and clinical outcomes.
- Specific biomarkers correlate with the risk and severity of irAE.
- Biomarker profiles can differ for efficacy and toxicity.
Conclusions:
- Biomarkers are essential for predicting CPI response and toxicity.
- Identifying predictive biomarkers can optimize patient selection for CPI therapy.
- Further research into biomarkers may improve CPI treatment strategies.
